Biblio Discovery — Demo Discovery Service

6 hasil untuk "Sangbin Lim"

Menampilkan 1–6 · 0,82 detik · RSS

  1. Artikel Jurnal

    Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into Immuno-Metabolism

    Anusha Angajala; Sangbin Lim; Joshua B. Phillips dkk.

    Frontiers in Immunology, Vol. 9 · 2018 · Inggris · DOAJ Scopus

    Lack of immune system cells or impairment in differentiation of immune cells is the basis for many chronic diseases. Metabolic changes could be the root cause for this immune cell impairment. These changes could be a result of altered transcription, cytokine production from surrounding cells, and…

  2. Artikel Jurnal

    Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib

    Sun Min Lim, MD, PhD; San-Duk Yang, PhD; Sangbin Lim, PhD dkk.

    JTO Clinical and Research Reports, Vol. 2 No. 6 · 2021 · Inggris · DOAJ Scopus

    Introduction: MET amplification is a frequently observed mechanism of resistance to osimertinib, and coinhibition strategy of MET and EGFR revealed promising results in recent clinical trials. Nevertheless, acquired resistance mechanisms to combined EGFR and MET inhibition are poorly understood. In…

  3. Artikel Jurnal

    Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models

    Sun Min Lim; San-Duk Yang; Sangbin Lim dkk.

    Therapeutic Advances in Medical Oncology, Vol. 14 · 2022 · Inggris · DOAJ Scopus

    Introduction: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that is approved for the use of EGFR -mutant non-small cell lung cancer (NSCLC) patients. In this study, we investigated the acquired resistance mechanisms in NSCLC patients and patient-derived preclinical models…

  4. Artikel Jurnal Teks lengkap

    Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

    Jiyeon Yun; Soo‐Hwan Lee; Seok-Young Kim dkk.

    Cancer Discovery · 2020 · Inggris · OpenAlex Scopus

    Abstract EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR–MET, has shown preclinical activity in TKI-sensitive EGFR-mutated NSCLC…

  5. Artikel Jurnal

    ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors

    Seol Hwa Shin; Eun Jin Ju; Jin Park dkk.

    Cancer Cell International, Vol. 23 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Background The B7-H3 protein, encoded by the CD276 gene, is a member of the B7 family of proteins and a transmembrane glycoprotein. It is highly expressed in various solid tumors, such as lung and breast cancer, and has been associated with limited expression in normal tissues and poor…

  6. Artikel Jurnal

    SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models

    Chun‐Bong Synn; Sung Eun Kim; Hee Kyu Lee dkk.

    Clinical & Translational Immunology, Vol. 11 No. 1 · 2022 · Inggris · DOAJ Scopus

    Abstract Objectives AXL‐mediated activation of aberrant tyrosine kinase drives various oncogenic processes and facilitates an immunosuppressive microenvironment. We evaluated the anti‐tumor and anti‐metastatic activities of SKI‐G‐801, a small‐molecule inhibitor of AXL, alone and in combination with…